Dear All (prepare for something that is delightfully different and marvelously wonkish AND with thanks to Lance Price for co-authoring this newsletter), Continuing with the theme in the 15 Aug 2025 newsletter (“Global livestock resistome: Antibiotic resistance is widespread!”) of ways to use sequencing of samples from the environment, we have today an amazing paper in
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), In the wake of the Sep 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR), it has been encouraging to see the continued discussion around Push and Pull incentives for antibacterial innovation and access (see the AMR.Solutions post-UNGA webpage for
Dear All, As a follow-on to the global commitments made during the 2024 UN General Assembly High-Level Meeting on AMR (UNGA 2024 HLM AMR), the Global Future Council on AMR of the World Economic Forum (WEF) authored the 2025 Davos Compact on AMR with review by the Quadripartite Joint Secretariate on AMR as a way for organizations to
Dear All, With thanks to alert reader Liam Sharkey, a post-doc in Melbourne, for the heads-up on this topic, I am very pleased to see the 17 June 2025 report from Australia entitled “Fighting Superbugs: A Subscription-Style Reimbursement Mechanism to Boost Australia’s Arsenal of Antimicrobial Medicines.” This paper is the output from a Nov 2024 roundtable in Canberra
Dear All (and with thanks to Lance Price for co-authoring this deeply wonkish newsletter), Today we turn to the idea of examining livestock manure for the presence of antibiotic resistance genes. You can easily see how this idea plays into the question of how to track and control AMR. Before we dive into the paper, however,
Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a report by Anthony McDonnell and a team led by the Center for Global Development in which they created economic estimates of the costs/values of action (and inaction) through 2050, based on 5 possible action/ inaction scenarios.
Dear All, I have learned that UK’s MHRA (Medicines & Healthcare products Regulatory Agency) is recruiting for the role of Chief Medical and Scientific Officer. As you would expect, the role is very senior! The person in the role will: Represent the MHRA across the medical and scientific communities Act as a senior advocate for evidence-based, effective
Dear All, Back in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes of a drug) for products for enteric fever, gonorrhea, neonatal sepsis, and urinary tract infections as guides for developers (see the 1 Sep 2019 newsletter for the original call for input and the link
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We wrote previously in (i) the 7 Dec 2023 newsletter (“How Italy should Push and Pull: New report as Italy takes the 2024 G7 chair”), (ii) the 17 Oct 2024 newsletter (“Italy funds CARB-X and announces pull incentive!”), and finally (iii) the 9 Jan
Dear All, BARDA have published an RFP (Request for Proposals) under which it would support clinical development and then stockpiling of an antibiotic for “treatment of bacterial pneumonia or bloodstream infections.” Here are the data you need to get started: RFP #: 75A50125R00005 https://sam.gov/opp/494fc05d7c4940abad0273cdb465079a/view Submission deadline is 26 Aug 2025 Quoting liberally from the online